Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
FibroGen ( (FGEN) ) just unveiled an update.
On December 29, 2025, FibroGen filed a certificate of amendment in Delaware to change its corporate name to Kyntra Bio, with the change and related bylaw update becoming effective at 4:30 p.m. Eastern Time on January 7, 2026. The company announced on January 7, 2026, that it is rebranding as Kyntra Bio to reflect its strategic transformation and sharpened focus on oncology and rare disease assets, and its common stock will begin trading on Nasdaq under the new ticker symbol KYNB on January 8, 2026, while retaining the same CUSIP number. Management framed 2025 as a pivotal year marked by the sale of FibroGen China, repayment of its senior secured term loan and extension of its cash runway into 2028, positioning the newly named Kyntra Bio to concentrate on advancing its mid- and late-stage pipeline, including the FG-3246/FG-3180 prostate cancer program and the U.S. development of roxadustat for myelodysplastic syndromes, with key clinical readouts from ongoing trials expected in 2026.
The most recent analyst rating on (FGEN) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.
Spark’s Take on FGEN Stock
According to Spark, TipRanks’ AI Analyst, FGEN is a Neutral.
FibroGen’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and financial instability. While the earnings call provided some positive strategic developments, the technical analysis and valuation indicate ongoing challenges. The stock’s low P/E ratio suggests potential undervaluation, but financial risks remain significant.
To see Spark’s full report on FGEN stock, click here.
More about FibroGen
Kyntra Bio, formerly FibroGen, is a San Francisco-based biopharmaceutical company focused on developing novel therapies for oncology and rare diseases. Its portfolio includes roxadustat, approved in Europe, Japan and other markets for anemia in chronic kidney disease, as well as FG-3246, a first-in-class CD46-targeting antibody-drug conjugate in Phase 2 for metastatic castration-resistant prostate cancer, and FG-3180, a related CD46-targeted PET imaging biomarker.
Average Trading Volume: 34,008
Technical Sentiment Signal: Sell
Current Market Cap: $36.13M
For detailed information about FGEN stock, go to TipRanks’ Stock Analysis page.